Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2019 1
2020 5
2021 7
2022 2
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Targeting KRAS in pancreatic cancer: new drugs on the horizon.
Bannoura SF, Uddin MH, Nagasaka M, Fazili F, Al-Hallak MN, Philip PA, El-Rayes B, Azmi AS. Bannoura SF, et al. Among authors: al hallak mn. Cancer Metastasis Rev. 2021 Sep;40(3):819-835. doi: 10.1007/s10555-021-09990-2. Epub 2021 Sep 9. Cancer Metastasis Rev. 2021. PMID: 34499267 Free PMC article. Review.
Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers.
Khan HY, Nagasaka M, Aboukameel A, Alkhalili O, Uddin MH, Bannoura S, Mzannar Y, Azar I, Beal E, Tobon M, Kim S, Beydoun R, Baloglu E, Senapedis W, El-Rayes B, Philip PA, Mohammad RM, Shields AF, Al-Hallak MN, Azmi AS. Khan HY, et al. Among authors: al hallak mn. bioRxiv [Preprint]. 2023 Mar 27:2023.03.27.534309. doi: 10.1101/2023.03.27.534309. bioRxiv. 2023. PMID: 37034616 Free PMC article. Updated. Preprint.
Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers.
Khan HY, Nagasaka M, Aboukameel A, Alkhalili O, Uddin MH, Bannoura SF, Mzannar Y, Azar I, Beal EW, Tobon ME, Kim SH, Beydoun R, Baloglu E, Senapedis W, El-Rayes BF, Philip PA, Mohammad RM, Shields AF, Al Hallak MN, Azmi AS. Khan HY, et al. Among authors: al hallak mn. Mol Cancer Ther. 2023 Dec 1;22(12):1422-1433. doi: 10.1158/1535-7163.MCT-23-0251. Mol Cancer Ther. 2023. PMID: 37703579 Free PMC article.
Gastrointestinal stromal tumor: a review of current and emerging therapies.
Al-Share B, Alloghbi A, Al Hallak MN, Uddin H, Azmi A, Mohammad RM, Kim SH, Shields AF, Philip PA. Al-Share B, et al. Among authors: al hallak mn. Cancer Metastasis Rev. 2021 Jun;40(2):625-641. doi: 10.1007/s10555-021-09961-7. Epub 2021 Apr 19. Cancer Metastasis Rev. 2021. PMID: 33876372 Review.
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions.
Kim DW, Schram AM, Hollebecque A, Nishino K, Macarulla T, Rha SY, Duruisseaux M, Liu SV, Al Hallak MN, Umemoto K, Wesseler C, Cleary JM, Springfeld C, Neuzillet C, Joe A, Jauhari S, Ford J, Goto K. Kim DW, et al. Among authors: al hallak mn. Future Oncol. 2024 Feb 13. doi: 10.2217/fon-2023-0824. Online ahead of print. Future Oncol. 2024. PMID: 38348690 Free article. Review.
Gastric Cancer Heterogeneity and Clinical Outcomes.
Sexton RE, Hallak MNA, Uddin MH, Diab M, Azmi AS. Sexton RE, et al. Among authors: hallak mna. Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820935477. doi: 10.1177/1533033820935477. Technol Cancer Res Treat. 2020. PMID: 32799763 Free PMC article.
22 results